A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor

PHASE1UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2021

Primary Completion Date

October 23, 2022

Study Completion Date

March 23, 2023

Conditions

Neoplasms

Interventions

DRUG

ABSK043 oral capsule

ABSK043 is a novel, oral small molecule inhibitor of PD-L1

Trial Locations (3)

RECRUITING

Icon Cancer Centre South Brisbane, Brisbane

RECRUITING

Peninsula & South Eastern Haematology and Oncology Group, Frankston

RECRUITING

Sydney South West Private Hospital, Liverpool